9 December 2015 - The Transparency Commission will consider the reimbursement of alirocumab (Praluent) for patients with hypercholesterolaemia and a new indication for aflibercept (Eylea).

For more details, go to: file:///Users/michaelwonder/Desktop/ordre_du_jour_ct_16122015.pdf [French]